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Abstract
Background: Breast magnetic resonance imaging (MRI) is the most sensitive imaging method for breast cancer
detection and is therefore offered as a screening technique to women at increased risk of developing breast
cancer. However, mammography is currently added from the age of 30 without proven benefits. The purpose of
this study is to investigate the added cancer detection of mammography when breast MRI is available, focusing on
the value in women with and without BRCA mutation, and in the age groups above and below 50 years.
Methods: This retrospective single-center study evaluated 6553 screening rounds in 2026 women at increased risk
of breast cancer (1 January 2003 to 1 January 2014). Risk category (BRCA mutation versus others at increased risk of
breast cancer), age at examination, recall, biopsy, and histopathological diagnosis were recorded. Cancer yield, false
positive recall rate (FPR), and false positive biopsy rate (FPB) were calculated using generalized estimating equations
for separate age categories (< 40, 40–50, 50–60, ≥ 60 years). Numbers of screens needed to detect an additional
breast cancer with mammography (NSN) were calculated for the subgroups.
Results: Of a total of 125 screen-detected breast cancers, 112 were detected by MRI and 66 by mammography:
13 cancers were solely detected by mammography, including 8 cases of ductal carcinoma in situ. In BRCA mutation
carriers, 3 of 61 cancers were detected only on mammography, while in other women 10 of 64 cases were detected
with mammography alone. While 77% of mammography-detected-only cancers were detected in women ≥ 50 years
of age, mammography also added more to the FPR in these women. Below 50 years the number of mammographic
examinations needed to find an MRI-occult cancer was 1427.
Conclusions: Mammography is of limited added value in terms of cancer detection when breast MRI is available for
women of all ages who are at increased risk. While the benefit appears slightly larger in women over 50 years of age
without BRCA mutation, there is also a substantial increase in false positive findings in these women.
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Background
Mammography-based screening for breast cancer re-
duces breast cancer-related mortality in the general
female population [1]. However, in women at in-
creased risk (e.g. those with a germline mutation in
the BRCA1 or BRCA2 genes) biennial mammographic
screening is insufficient due to low sensitivity and
high rates of interval cancers [2–5]. Consequently,
these women who have a higher-than-average lifetime
risk of breast cancer (approximately ≥ 20–25% life time
risk (LTR)) are invited to intensified screening programs
[6, 7], consisting of dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) and mammography. The
sensitivity and specificity of these screening programs have
been reported to be as high as 97% and 98%, respectively
[4, 8–12].
Recent studies question the added cancer detection of
mammography in this population, especially in BRCA
mutation carriers [13]. In the study of Kuhl et al. [10],
MRI proved to be the most important contributor to
stage reduction. Although these results show the super-
iority of breast MRI compared to mammography for the
detection of cancers, routine mammography is currently
recommended for all women, even at a relatively young
age. Various authors have proposed to cancel mammo-
graphic screening in young women also screened with
breast MRI, especially in BRCA1 mutation carriers. In
these BRCA1 mutation carriers, the mammographic sen-
sitivity is exceedingly low, reported as low as 35% [14].
This is believed to be caused not only by the on-average
dense breasts of these women, but also by the mammo-
graphic benign-like features of BRCA1-associated can-
cers [15, 16]. Berrington de Gonzalez et al. reported that
there is little to no benefit of mammographic screening
under the age of 35 [17]. Additionally, concerns are
raised about the risk of radiation-induced cancers in
these women, as BRCA mutation carriers have increased
susceptibility to radiation [17, 18].
Although guidelines may vary per country, mammo-
graphic screening in BRCA mutation carriers is advised
from the age of 30 years [6, 7]. However, the actual
benefits in terms of tumor detection of the addition of
mammography at such a young age are still unclear. Fur-
thermore, additional findings on the mammogram might
lead to an increase in false positive recalls in the screen-
ing program.
Hence, there is a clinical need to find an optimal regi-
men for intensified screening programs to prevent un-
necessary recalls, biopsies, and radiation exposure. The
purpose of this study is to evaluate the added cancer de-
tection and false positive rates with mammography when
breast MRI is available in a population of women at in-
creased risk of developing breast cancer. Differences in
the complementary value of mammography in women
below and above 50 years of age, and in BRCA mutation
carriers versus others at increased risk of breast cancer
were assessed.
Methods
This retrospective study was approved by our local insti-
tutional review board and the requirement for informed
consent was waived.
Screening program
The increased risk screening program was evaluated for
the period 1 January 2003 until 1 January 2014. The pro-
gram starts at age 25 years for BRCA mutation carriers,
who undergo yearly MRI. At the age of 30 years a yearly
mammography is added. Women with an LTR of ≥ 20–
25% are screened from the start with mammography
and MRI; starting ages differ by the reason for screening
[19]. Furthermore, women may have been enrolled in
the program at a later point in time after detection of a
specific factor that increases their personal risk. We pre-
viously reported on the overall screening performance in
this cohort [20].
Case selection
The local database was searched to identify all screening
MRI and mammography examinations. Women were in-
cluded when an MRI examination was considered a screen-
ing examination (inquiry at the radiology department was
for screening purposes in asymptomatic women). Women
were excluded when no mammography was performed
within 6 months of the screening MRI. Risk category, age,
screening tests performed, eventual recall for workup of
screen-detected abnormalities and histopathological diag-
nosis were recorded when available.
Image acquisition
MRI acquisition and protocols varied over time and have
previously been reported in detail [21]. In short: examina-
tions were performed on either a 1.5 or 3.0 Tesla Siemens
scanner (Magnetom Avanto, Magnetom Sonata, Magne-
tom symphony or Magnetom Trio) using a dedicated
bilateral breast coil. Patients were imaged in the prone
position. A transverse or coronal three-dimensional
T1-weighted gradient-echo dynamic sequence was per-
formed before contrast agent administration followed by
four or five post-contrast sequences. Various gadolinium
chelates were used as a contrast agent, administered at a
dose of 0.1 mmol/kg or 0.2 mmol/kg body weight using a
power injector (Medrad, Warrendale, PA, USA) at a flow
rate of 2.5 mL/s, followed by a saline flush. Premenopausal
women were scheduled in the 6th to 12th day of their
menstrual cycle.
Mammograms were obtained in two directions (med-
io-lateral oblique and cranio-caudal) with a full-field
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digital mammography machine (GE Senograph 2000 or
GE Senograph DS, GE, Fairfield, CT, USA). Additional
views and spot compression views were performed at
request of the evaluating radiologist.
Image interpretation
The Breast Imaging Reporting and Data system (BI-R-
ADS) [22, 23] was used for evaluation. All examinations
were evaluated by one of eight breast radiologists with
experience ranging from 0.5 to 23 years after certifica-
tion. Images were reported using a dedicated breast MRI
workstation (versions of DynaCAD, Invivo, Philips, Best,
the Netherlands). Mammograms were evaluated together
with MRI examinations when these examinations were
acquired the same day. In general, biopsies were per-
formed for lesions classified as BI-RADS 4 and 5, and a
subset of lesions classified as BI-RADS 3. The remainder
of BI-RADS 3 lesions underwent short-term follow up.
Ground truth
For BI-RADS 3 lesions with a short-term follow-up rec-
ommendation, at least 1 year of clinical follow up was
required to confirm benignity. A cross-computer search
of our pathology records was performed to identify all
biopsies performed. We subsequently analyzed if the bi-
opsy was triggered by screening results or whether the
woman presented with symptoms. To ensure detection
of all cancers, the database was also linked to the nation-
wide population-based Netherlands Cancer Registry (NCR).
Data analysis
Pathology results were grouped into malignant (in situ,
invasive, and metastatic cancer) and benign lesions (all
other findings). Only screen-detected cancers were in-
vestigated, which were defined as cancers diagnosed
after diagnostic workup initiated by screening results.
We separated screen-detected cancers by mammog-
raphy, MRI, or both based on radiological reports of the
respective modalities (or report sections when mammo-
grams and MRI were reported simultaneously).
Cancer yield, false positive recall rate (FPR) and false
positive biopsy rate (FPB) for mammography, MRI, and
the combination were calculated. Cancer yield was de-
fined as the number of screen-detected cancers per 1000
screening rounds. An FPR or FPB was defined as a
woman who was recalled/biopsied and was considered
disease-free after workup and/or after at least 1 year of
clinical follow up. The FPR/FPB were defined as the
number of FPRs/FPBs per 1000 screening rounds.
Two risk categories were evaluated (BRCA mutation
carriers and all others). The BRCA mutation carriers
group also included first-degree untested relatives. Ex-
aminations were grouped into four age categories to
investigate the influence of age (< 40, 40–50, 50–60, ≥
60 years).
Statistical analysis
Descriptive statistics were extracted. The chi-square (χ2)
test was applied to compare differences between groups
in demographics, in proportion of breast cancer, invasive
cancer, ductal carcinoma in situ (DCIS), tumor grade,
and false positives. Chi-square trend-tests were per-
formed to investigate the distribution of parameters
across age categories. Repeated screening results were
summarized to form binomial counts for each woman to
estimate cancer yield, FPR, and FPB. For each woman,
the number of true-positive and true-negative screens
per modality, and the number of screening visits with or
without breast cancer detected were counted. In this
way, binomial counts per modality were calculated and
analyzed. As the dependent variable was assumed to fol-
low a binomial distribution, generalized estimating equa-
tions (GEE) were applied. The binomial proportions
were modeled and conducted separately for cancer yield,
FPR, and FPB, using a compound symmetry correlation
structure. The analysis was conducted separately for
each age category, modality, and risk category. After ap-
plying the Bonferroni correction, a two-sided p value of
0.013 was considered statistically significant. The num-
ber of mammography screens needed (NSN) to detect
one breast cancer that was missed by MRI was calcu-
lated by dividing the number of mammography screens
performed by the number of breast cancers detected by
mammography alone. All statistics were performed using
SPSS (version 22, SPSS Inc., Chicago, IL, USA).
Results
Study population
Final analysis included 2026 women with 6553 screening
rounds (Table 1 and Table 2): 125 screen-detected cancers
were identified of which 13 and 59 were only detected by
mammography or MRI, respectively (p < 0.001). In total,
112 cancers were seen on MRI and 66 on mammography.
Overall, no significant difference was found between
tumor grade of cancers detected by mammography or
MRI (p = 0.193). Mammography detected a significantly
larger proportion of pure DCIS (16/66 (24%) and 15/112
(13%) for mammography or MRI, respectively, p < 0.001).
We did not observe a difference in the grade of DCIS
detected with mammography or MRI (p = 0.436).
Mammography-detected breast cancers
The majority of cancers detected only with mammog-
raphy consisted of pure DCIS (pTis) (8/13, 62%, Table 3).
Most women who were diagnosed with pure DCIS
were ≥ 50 years of age (6/8, 75%, Table 3). The remaining
five women with an invasive cancer detected only at
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mammography were aged 35, 53, 54, 55, and 56 years,
respectively. Overall, cancer detection with mammog-
raphy only was higher in women ≥ 50 years old, than in
those below 50, though this was not significant (3/58 vs.
10/67, p = 0.07). All pure mammography-detected breast
cancers were detected in follow-up rounds. The NSN for
the overall population and the defined subgroups are
presented in Table 4. There was no cancer that was not
reported by MRI in the first rounds of screening, making
an estimate of NSN not applicable. Our results show
that the NSN was highest in the lowest age categories.
Whether there is a difference in age groups between
women with a proven BRCA mutation and women with-
out is difficult to determine, since we did not observe
only mammographically detected breast cancers in
BRCA mutation carriers under 50 years of age, but
overall the added cancer detection in BRCA mutation
carriers was slightly lower than in other women at in-
creased risk (3/61 vs. 10/64, p = 0.05).
Cancer yield
Cancer yield increased over time, with a peak at the 50–60
years age category (Fig. 1). The difference between cancers
detected by MRI and the combination (mammography +
MRI) seemed to increase with age (< 40 years, 0.47; 40–
50 years, 0.93; 50–60 years, 4.26; ≥ 60 years, 2.93 per 1000
examinations), pointing to a possible increased added value
of mammography in higher age categories (Fig. 2), which
was the strongest in the 50–60 years categories both in the
BRCA mutation carriers and others. The increase in breast
cancer yield by the addition of mammography was not
significant in any risk category (p ≥ 0.303). Table 5 summa-
rizes cancer yield, FPR, and FPB.
False positives
For FPRs, mammography added 103 FPRs on top of 112
FPRs based on both mammography and MRI, and 287
FPRs based on MRI alone. Overall, mammography sig-
nificantly added to the FPRs (p = 0.001), especially in the
group of women without a BRCA mutation (p = 0.001).
The relative increase in the FPR due to mammography
was greater in the higher age groups (< 40 years, 14%;
40–50 years, 27%; 50–60 years, 44%; ≥ 60 years, 61%,
Fig. 2). This was significant in women without a BRCA
mutation (p < 0.001). In total 35 FPBs were performed
based on mammography alone. This did not lead to a
significant increase in the overall FPBs (p = 0.013), or in
any of the subcategories (p ≥ 0.323). Completely omitting
mammography from the screening regimen would have
led to a reduction of 21% (103/502) in FPRs and 11%
(35/331) in FPBs.
Discussion
This study evaluated the added value of mammography
on top of MRI in a multimodal imaging screening pro-
gram for women who are at intermediate or high risk of
developing breast cancer in a single academic institute.
The addition of mammography translated mostly to the
detection of a small number of DCIS cases that were oc-
cult on MRI. However, five additional invasive carcinomas
were also detected. The number of mammography screen-
ing examinations needed to detect an MRI occult cancer
depended on age, and was very high in women under 40
years old. In addition, adding mammography led to a
slight increase in false-positive recalls and biopsies.
Screening, with the aim of early detection of (pre-) ma-
lignant breast lesions to decrease breast cancer-related
mortality, is a well-accepted risk-reducing strategy for
most women at increased risk of developing breast cancer
[24]. MRI is considered the most accurate imaging modal-
ity [10, 12, 25, 26]. Mammography is currently added to
most screening regimens that include MRI to detect calci-
fied breast lesions that may be visualized with mammog-
raphy but not with MRI [27, 28]. In our study, 8 out of 13
cancers (62%) were MRI-occult DCIS that were detected
based on microcalcifications on the mammogram. The
five invasive cancers that were detected only with mam-
mography, were also found because of microcalcifications.
Table 1 Demographic data and risk profile
All women BRCA mutation carriersa Others at increased riskb
Number 2026 744 1282
Age
Mean 44.7 40.4 47.2
SD 11.7 11.0 11.3
Median 44 39 47
Range 21–91 23–75 21–91
Number of cancers 125 61 64
Number of false positive recalls 502 165 337
Number of false positive biopsies 331 117 214
aBRCA mutation carriers include 454 BRCA1 mutation carriers and 290 BRCA2 mutation carriers
bOthers at increased risk include 561 women with a family history of breast cancer, 515 women with a personal history of breast cancer, and 206 others
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Table 2 Population and breast cancer characteristics in the cohort
Age < 40 years Age 40–50 years Age 50–60 years Age ≥ 60 years Overall p valuea
Women (N)
BRCA 388 258 182 75 903 <0.001
Others 329 504 482 273 1588 0.014
Overall 717 762 664 348 2491 <0.001
Exams (N)
BRCA 1113 737 568 190 2608 <0.001
Others 716 1313 1265 651 3945 0.046
Overall 1829 2050 1833 841 6553 <0.001
BC (N)
Mammography 13 13 25 15 66 0.253
Mammography only 1 2 8 2 13 0.202
MRI 25 30 37 20 112 0.697
MRI only 13 19 20 7 59 0.254
Overall 26 32 45 22 125 0.963
Invasive tumor (N)
Mammography 13 9 16 12 50 0.771
Mammography only 1 0 4 0 5 0.822
MRI 24 25 30 18 97 0.496
MRI only 12 16 18 6 52 0.253
Overall 25 25 34 18 102 0.540
DCIS (N)
Mammography 0 4 9 3 16 0.073
Mammography only 0 2 5 1 8 0.281
MRI 1 5 7 2 15 0.036
MRI only 1 3 2 1 7 0.848
Overall 1 7 11 4 23 0.164
Tumor grade of all cancers (invasive and in situ) (N)
Grade 1
Mammography 1 1 4 1 7 0.536
Mammography only 0 0 1 0 1 0.655
MRI 3 4 5 5 17 0.384
MRI only 2 3 2 4 11 0.442
Grade 2
Mammography 1 5 7 4 17 0.171
Mammography only 0 1 2 1 4 0.317
MRI 3 10 17 6 36 0.170
MRI only 2 6 12 3 23 0.335
Grade 3
Mammography 11 7 11 6 35 0.339
Mammography only 1 1 2 1 5 0.822
MRI 17 15 15 5 52 0.010
MRI only 7 9 6 0 22 0.009
Missing 2 1 3 4 10 0.197
FPR (N)
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By mammography alone, only one invasive cancer (grade
3) was detected in a BRCA mutation carrier, at the age of
56 years. Our results are in line with the meta-analysis of
Heijnsdijk et al. [29], who reported only one invasive can-
cer detected by mammography alone in BRCA1 mutation
carriers across four breast cancer screening trials of
women at high risk of developing breast cancer. Obdeijn
et al. [13] also reported little benefit of mammography
screening in younger women with a BRCA1 mutation. In
their study, omitting mammography from the screening
regimen would have led to two missed DCIS cases in
women aged 50 and 67 years. Obdeijn et al. suggested to
increase the starting age for mammography screening in
women with BRCA1 mutations to 40 years. Interestingly,
in our study all cancers detected by mammography alone
were detected in follow-up rounds, which might point to
some increased value in higher age groups. It may also be
partly explained by the fact that BRCA mutation carriers
start with MRI alone, and only from the age of 30 years is
mammography added. Our results suggest that the detec-
tion of MRI-occult breast cancers is very rare in all
women younger than 40 years. Of 13 MRI-occult cancers
(both DCIS and invasive cancers and both high and low
grade), 10 were observed in women ≥ 50 years old in our
Table 2 Population and breast cancer characteristics in the cohort (Continued)
Age < 40 years Age 40–50 years Age 50–60 years Age ≥ 60 years Overall p valuea
Mammography 63 75 55 22 215 <0.001
Mammography only 22 38 28 15 103 0.115
MRI 159 143 72 25 399 <0.001
MRI only 118 106 45 18 287 <0.001
Overall 181 181 100 40 502 <0.001
FPB (N)
Mammography 35 46 32 9 122 <0.001
Mammography only 6 15 11 3 35 0.258
MRI 114 113 51 18 296 <0.001
MRI only 85 82 30 12 209 <0.001
Overall 120 128 62 21 331 <0.001
BC breast cancer (invasive cancer and ductal carcinoma in situ (DCIS)), MRI magnetic resonance imaging, FPR false positive recall, FPB false positive biopsy
aChi-square test for trend was performed for the fraction of the overall population
Table 3 Breast cancers detected solely by mammography
Number Risk category Ipsi/ contrab Age Tumor type Tumor sizea Tumor grade ER-status PR- status H2N-status Nodal status 1st round
versus FU
1 BRCA1 N/A 50 DCIS 6 2 – – – 0 FU
2 Family N/A 43 DCIS 7 2 – – – 0 FU
3 Family N/A 48 DCIS – 3 – – – 0 FU
4 Personal Ipsi 55 DCIS 23 – – – – 0 FU
5 Personal Contra 58 DCIS – – – – – 0 FU
6 Personal Contra 69 DCIS 6 2 – – – 0 FU
7 Other N/A 61 DCIS 21 3 – – – – FU
8 Personal Contra 55 DCIS – 3 – – – 0 FU
9 BRCA2 N/A 57 DCIS1 6 – Positive Positive Negative 0 FU
10 BRCA1 N/A 56 IDC 8 3 Positive Positive Negative 0 FU
11 Family N/A 35 IDC 4 3 Positive Positive – 0 FU
12 Family N/A 53 Tubular 3 1 Positive Positive Negative 0 FU
13 Other N/A 54 ILC 23 2 Positive Positive Negative 1mi FU
The symbol “–” indicates not available
N/A not applicable, ipsi ipsilateral, contra contralateral, ER estrogen receptor, PR progesterone receptor, DCIS ductal carcinoma in situ, IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma, FU follow up
aPathological tumor size (in mm), in case of multi-centric tumors (case 13) the diameter of the largest tumor is mentioned
bBreast cancer in the ipsilateral or contralateral breast in patients with a personal history of breast cancer
1DCIS with micro-invasive growth
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Table 4 Number of screens needed (NSN) for one additional mammography-only detected cancer
Age group (years) Number of breast cancers Number of screens Breast cancers detected
by mammography only
NSN for mammography
to detect breast cancer
missed by MRI
Overall < 40 years 26 1829 1 1829
40–50 years 32 2050 2 1025
50–60 years 45 1833 8 229
≥ 60 years 22 841 2 421
BRCA < 40 years 17 1113 0 N/A
40–50 years 14 737 0 N/A
50–60 years 26 568 3 189
≥ 60 years 4 190 0 N/A
No BRCA < 40 years 9 716 1 716
40–50 years 18 1313 2 657
50–60 years 19 1265 5 253
≥ 60 years 18 651 2 326
Follow up < 40 years 17 1112 1 1112
40–50 years 20 1447 2 724
50–60 years 28 1342 8 168
≥ 60 years 11 626 2 313
BRCA < 40 years 12 725 0 N/A
40–50 years 9 554 0 N/A
50–60 years 18 433 3 144
≥ 60 years 0 152 0 N/A
No BRCA < 40 years 5 387 1 387
40–50 years 11 893 2 447
50–60 years 10 909 5 182
≥ 60 years 11 474 2 237
MRI magnetic resonance imaging, N/A not applicable, the first round was not shown in the table as no mammography-only cancers were detected in the first round
Fig. 1 Cancer yield. Cancer yield in women with a BRCA mutation versus all others (family, personal, and others). The tag “combination” indicates
the combination of mammography + magnetic resonance imaging (MRI)
Vreemann et al. Breast Cancer Research  (2018) 20:84 Page 7 of 12
population, which is in line with the results reported by
Narayan et al. [30]. It should be noted that according to
Vreemann et al. [31] 3 of the 13 MRI-occult cancers in
this study were in retrospect visible on MRI, including 2
invasive ductal carcinoma (IDC) and 1 DCIS. In our study,
raising the starting age of mammography to 40 years
would have led to missing one invasive ductal cancer (high
grade) in a woman with a positive family history of breast
cancer but without a known BRCA mutation, and no
DCIS would have been missed. In retrospect, this invasive
cancer was one of the visible lesions on the MRI and was
therefore not truly occult [31, 32]. Additionally, while in
older women the additional detection of breast cancer in-
creases with the addition of mammography, this is counter-
balanced by an increase in false positive findings. These
results are supported by the data of Phi and coworkers [33].
Other imaging modalities may be used to detect add-
itional cancers on top of MRI. Unfortunately, handheld
ultrasound or even automated breast ultrasound has
been shown to be of limited value in a screening setting
where MRI is available [10–12, 25, 34]. Digital breast
tomosynthesis (DBT) has also been shown to increase
the cancer detection rate and decrease the number of
FPRs when compared to mammography alone in women
at average risk [35, 36]. However, there is no consensus
on the added value of DBT when breast MRI is available
[37]. Therefore, current guidelines only include mam-
mography. The gain in sensitivity with mammography
seems to come mostly from the detection of lesions
presenting with calcifications. DBT appears to be of
relatively equal value to mammography for this purpose,
but at a higher dose [38, 39]. Since younger women
at high risk and in particular BRCA mutation carriers
have been shown to be more susceptible to develop-
ing radiation-induced cancers [17, 18], replacing
mammography with DBT might not be beneficial for
women screened with MRI. Berrington de Gonzalez
et al. [17] reported no net benefit of mammography
surveillance before the age of 35 years in women with
a BRCA mutation and recommended to limit the ra-
diation dose by raising the age for undergoing mam-
mography. Our results indicate that raising the age
Fig. 2 False positive rates. False positive rates for recall (FPR) (a) and for biopsy (FPB) (b) for women with a BRCA mutation versus all others
(family, personal, and others). The tag “combination” indicates the combination of mammography + magnetic resonance imaging (MRI)
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Table 5 Cancer yield, FPR and FPB results for mammography (A), MRI (B), and the combination (C)
Age category Risk category Cancer yielda (95% CI) FPRa (95% CI) FPBa (95% CI)
A. Mammography
< 40 years Overall 6.54 (3.73–11.46) 36.06 (27.57–47.03) 19.48 (13.73–27.58)
BRCA 7.17 (3.61–14.18) 26.96 (18.07–40.03) 15.52 (9.03–26.57)
No BRCA 5.61 (2.10–14.89) 49.62 (34.62–70.64) 24.94 (15.94–38.83)
40–50 years Overall 6.35 (3.71–10.83) 40.44 (31.53–51.72) 24.23 (17.66–33.16)
BRCA 6.78 (2.85–16.02) 18.90 (11.26–31.56) 12.21 (6.37–23.30)
No BRCA 6.11 (3.08–12.06) 52.66 (39.80–69.38) 30.56 (21.36–43.55)
50–60 years Overall 13.57 (9.21–19.94) 33.28 (24.94–44.29) 18.38 (12.60–26.75)
BRCA 26.10 (15.93–42.47) 10.56 (4.75–23.31) 8.85 (3.67–21.15)
No BRCA 7.89 (4.26–14.58) 43.06 (31.68–58.27) 22.16 (14.61–33.47)
≥ 60 years Overall 17.72 (10.81–28.93) 25.82 (16.76–39.58) 10.88 (5.64–20.90)
BRCA 21.48 (7.99–56.49) 10.69 (2.64–42.22) 0.00 (N/A)
No BRCA 16.90 (9.54–29.77) 30.38 (19.27–47.57) 14.14 (7.31–27.15)
Overall Overall 9.95 (7.80–12.69) 36.42 (31.42–42.19) 20.05 (16.49–24.37)
BRCA 12.44 (8.75–17.65) 20.65 (15.32–27.77) 12.56 (8.50–18.51)
No BRCA 8.33 (5.95–11.65) 47.08 (39.74–55.71) 24.95 (19.91–31.24)
B. MRI
< 40 years Overall 13.09 (8.80–19.44) 87.25 (74.68–101.71) 62.30 (51.89–74.63)
BRCA 14.31 (8.81–23.16) 75.49 (60.59–93.70) 56.72 (44.03–72.79)
No BRCA 11.22 (5.61–22.31) 104.96 (84.38–129.84) 70.70 (54.44–91.35)
40–50 years Overall 14.06 (9.83–20.07) 70.45 (59.44–83.31) 55.95 (46.39–67.33)
BRCA 18.86 (11.26–31.42) 47.03 (34.06–64.61) 34.73 (23.93–50.15)
No BRCA 11.37 (6.91–18.66) 82.49 (67.63–100.27) 67.55 (54.44–83.53)
50–60 years Overall 19.56 (14.16–26.96) 41.64 (32.53–53.16) 29.88 (22.29–39.94)
BRCA 40.37 (27.00–59.96) 44.36 (29.42–66.36) 30.66 (18.27–51.02)
No BRCA 10.25 (5.97–17.55) 40.08 (29.42–54.38) 29.41 (20.59–41.84)
≥ 60 years Overall 23.56 (15.39–35.93) 29.04 (19.45–43.15) 20.49 (12.72–32.85)
BRCA 21.48 (7.99–56.49) 10.85 (2.66–43.12) 10.85 (2.66–43.12)
No BRCA 24.40 (15.23–38.87) 34.37 (22.63–51.89) 23.31 (14.04–38.45)
Overall Overall 16.64 (13.81–20.04) 62.52 (56.37–69.29) 46.27 (41.11–52.06)
BRCA 22.08 (17.03–28.60) 56.98 (48.07–67.42) 41.81 (34.35–50.80)
No BRCA 13.10 (10.02–17.10) 66.13 (58.03–75.27) 49.21 (42.42–57.03)
C. Combination
< 40 years Overall 13.56 (9.24–20.10) 99.78 (86.35–115.04) 65.68 (54.96–78.31)
BRCA 14.31 (8.81–23.16) 85.01 (69.45–103.66) 60.34 (47.29–76.70)
No BRCA 12.65 (6.58–24.21) 121.64 (99.00–148.59) 73.85 (56.96–95.26)
40–50 years Overall 15.02 (10.64–21.17) 89.74 (77.29–103.98) 63.26 (53.13–75.18)
BRCA 18.86 (11.26–31.42) 57.42 (42.61–76.97) 42.39 (29.86–59.85)
No BRCA 12.89 (8.10–20.48) 107.19 (90.27–126.84) 74.68 (61.11–90.97)
50–60 years Overall 23.82 (17.82–31.76) 60.11 (48.79–73.85) 36.58 (28.05–47.59)
BRCA 45.29 (31.14–65.43) 47.62 (32.20–69.90) 33.91 (20.91–54.54)
No BRCA 14.16 (8.97–22.29) 65.53 (51.26–83.42) 37.51 (27.28–51.37)
≥ 60 years Overall 26.49 (17.31–40.36) 46.86 (34.05–64.17) 24.16 (15.57–37.33)
BRCA 21.48 (7.99–56.49) 22.05 (8.12–58.46) 10.85 (2.66–43.12)
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limit of supplemental mammography screening to the
age of 40 years should be considered, not only for
BRCA germline mutation carriers, but for all women
at increased risk of developing breast cancer.
A further reason for this recommendation is that
population-based mammography screening programs
have been criticized because of overdiagnosis and over-
treatment of non-fatal breast disease detected during
screening [40]. Overdiagnosis, defined as the detection of
a breast cancer at screening that would have never been
identified clinically in the lifetime of the woman, has been
reported as between 1 and 10% [41]. Our results suggest
that adding mammography screening to breast MRI may
contribute to overdiagnosis because of the preferential
detection of relatively indolent (pre-) malignant subtypes
such as low-grade calcified ductal in situ carcinoma as de-
scribed in a previous study [20]. These cancers might be
biologically irrelevant compared to invasive and in situ
cancers detected with MRI that tend to be of higher grade
and are usually detected at an earlier stage [10, 37]. How-
ever, this is not evident from our data.
Our study has some limitations. It is a single-center
study in a tertiary referral center with a large, high-risk
screening program that might not be fully generalizable
to the whole breast imaging community. In addition,
due to the retrospective nature of the study, some of the
MRI and mammography examinations were evaluated
simultaneously, which might affect the screening out-
comes either positively or negatively. Breast density and
background parenchymal enhancement were often not
reported and therefore not used in this analysis. While
the study describes a long time-span, the absolute num-
ber of cancers detected is still small, which might lead to
underpowered results. Therefore, more studies are
required to confirm our findings.
Conclusions
In conclusion, mammography does not appear to signifi-
cantly add to cancer yield, albeit our results must be
interpreted with the relatively small number of cancers
in our study. In BRCA mutation carriers the added can-
cer detection with mammography is even less than for
women without BRCA mutation. Especially in younger
women, the number of mammography screens needed
to detect one additional cancer is very high, and increas-
ing the starting age for mammography (if at all) seems
safe to maximize the benefits of MRI screening. In
higher age groups mammography does add to the detec-
tion rates, but also leads to an increase in FPR and FPB.
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Table 5 Cancer yield, FPR and FPB results for mammography (A), MRI (B), and the combination (C) (Continued)
Age category Risk category Cancer yielda (95% CI) FPRa (95% CI) FPBa (95% CI)
No BRCA 27.87 (17.39–44.38) 54.21 (38.71–75.43) 28.06 (17.67–44.30)
Overall Overall 18.68 (15.65–22.27) 79.65 (72.70–87.21) 51.73 (46.28–57.78)
BRCA 23.17 (18.00–29.79) 65.59 (56.09–76.55) 46.14 (38.31–55.47)
No BRCA 15.74 (12.28–20.15) 89.14 (79.65–99.64) 55.39 (48.20–63.57)
aGeneral estimating equations were used to calculate performance measures, correcting for multiple screening rounds within the same patient. All measurements
are per 1000 examinations
MRI magnetic resonance imaging, N/A no cancers, recalls, or biopsies were found in this category and no 95% CI of this measure could be calculated, 95% CI Wald
95% confidence intervals
Vreemann et al. Breast Cancer Research  (2018) 20:84 Page 10 of 12
Received: 11 December 2017 Accepted: 10 July 2018
References
1. Nystrom L, Bjurstam N, Jonsson H, Zackrisson S, Frisell J. Reduced breast
cancer mortality after 20+ years of follow-up in the Swedish randomized
controlled mammography trials in Malmo, Stockholm, and Goteborg. J Med
Screen. 2017;24(1):34-42.
2. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT,
Weber B, Lenoir G, Chang-Claude J, et al. Genetic heterogeneity and
penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer
families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;
62(3):676–89.
3. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First
experiences in screening women at high risk for breast cancer with MR
imaging. Breast Cancer Res Treat. 2000;63(1):53–60.
4. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM,
Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, et al. Efficacy of MRI and
mammography for breast-cancer screening in women with a familial or
genetic predisposition. N Engl J Med. 2004;351(5):427–37.
5. Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M,
Horowitz E, El-Tamer MB, Schnabel FR. The development of interval breast
malignancies in patients with BRCA mutations. Cancer. 2004;100(10):2079–83.
6. Mann RM, Kuhl CK, Kinkel K, Boetes C, Breast MRI. Guidelines from the
European Society of Breast Imaging. Eur Radiol. 2008;18(7):1307–18.
7. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E,
Pisano E, Schnall M, Sener S, et al. American Cancer Society guidelines for
breast screening with MRI as an adjunct to mammography. CA Cancer J
Clin. 2007;57(2):75–89.
8. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ,
Griebsch I, Hoff RJ, Kessar P, et al. Screening with magnetic resonance
imaging and mammography of a UK population at high familial risk of
breast cancer: a prospective multicentre cohort study (MARIBS). Lancet.
2005;365(9473):1769–78.
9. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE,
Wasser MN, Bergers E, Kok T, Muller SH, et al. BRCA1-associated breast
cancers present differently from BRCA2-associated and familial cases: long-
term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;
28(36):5265–73.
10. Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig R, Tombach B,
Leutner C, Rieber-Brambs A, Nordhoff D, et al. Prospective multicenter
cohort study to refine management recommendations for women at
elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28(9):
1450–7.
11. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR,
DeBoer G, Yaffe MJ, Messner SJ, et al. Surveillance of BRCA1 and BRCA2
mutation carriers with magnetic resonance imaging, ultrasound,
mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.
12. Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, Rudas M,
Singer CF, Helbich TH. Triple-modality screening trial for familial breast
cancer underlines the importance of magnetic resonance imaging and
questions the role of mammography and ultrasound regardless of patient
mutation status, age, and breast density. J Clin Oncol. 2015;33(10):1128–35.
13. Obdeijn IM, Winter-Warnars GA, Mann RM, Hooning MJ, Hunink MG, Tilanus-
Linthorst MM. Should we screen BRCA1 mutation carriers only with MRI? A
multicenter study. Breast Cancer Res Treat. 2014;144(3):577–82.
14. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber
AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast
magnetic resonance imaging. JAMA. 2006;295(20):2374–84.
15. Schrading S, Kuhl CK. Mammographic, US, and MR imaging phenotypes of
familial breast cancer. Radiology. 2008;246(1):58–70.
16. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M,
Eggermont A, Klijn J, Meijers-Heijboer H, van der Kwast T, Brekelmans C. A
BRCA1/2 mutation, high breast density and prominent pushing margins of
a tumor independently contribute to a frequent false-negative
mammography. Int J Cancer. 2002;102(1):91–5.
17. Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk
of radiation-induced breast cancer from mammographic screening for
young BRCA mutation carriers. J Natl Cancer Inst. 2009;101(3):205–9.
18. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E,
Antoniou AC, Wagner T, Simard J, Evans G, et al. Effect of chest X-rays on the
risk of breast cancer among BRCA1/2 mutation carriers in the international
BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-
HEBON, and IBCCS Collaborators’ Group. J Clin Oncol. 2006;24(21):3361–6.
19. NABON: Breast Cancer Guideline. 2012.
20. Vreemann S, Gubern-Merida A, Schlooz-Vries MS, Bult P, van Gils CH,
Hoogerbrugge N, Karssemeijer N, Mann RM. Influence of risk category and
screening round on the performance of an MR imaging and
mammography screening program in carriers of the BRCA mutation and
other women at increased risk. Radiology. 2018;286(2):443-51.
21. Dalmis MU, Litjens G, Holland K, Setio A, Mann R, Karssemeijer N, Gubern-
Merida A. Using deep learning to Segment breast and fibroglanduar tissue
in MRI volumes. Med Phys. 2017;44(2):533-46.
22. Edwards SD, Lipson JA, Ikeda DM, Lee JM. Updates and revisions to the BI-
RADS magnetic resonance imaging lexicon. Magn Reson Imaging Clin N
Am. 2013;21(3):483–93.
23. Molleran V, Mahoney MC. The BI-RADS breast magnetic resonance imaging
lexicon. Magn Reson Imaging Clin N Am. 2010;18(2):171–85. vii
24. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E,
Foulkes WD, Domchek S, Ainsworth P, Isaacs C, et al. Predictors of
contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2
mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol.
2008;26(7):1093–7.
25. van Zelst JCM, Mus RDM, Woldringh G, Rutten M, Bult P, Vreemann S, de
Jong M, Karssemeijer N, Hoogerbrugge N, Mann RM. Surveillance of women
with the BRCA1 or BRCA2 mutation by using biannual automated breast
US, MR imaging, and mammography. Radiology. 2017;285(2):376-88.
26. Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G,
Vergnaghi D, Federico M, Cortesi L, Corcione S, et al. Multicenter
surveillance of women at high genetic breast cancer risk using
mammography, ultrasonography, and contrast-enhanced magnetic
resonance imaging (the high breast cancer risk Italian 1 study): final results.
Investig Radiol. 2011;46(2):94–105.
27. Sung JS, Stamler S, Brooks J, Kaplan J, Huang T, Dershaw DD, Lee CH, Morris
EA, Comstock CE. Breast cancers detected at screening MR imaging and
mammography in patients at high risk: method of detection reflects tumor
histopathologic results. Radiology. 2016;280(3):716–22.
28. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S,
Houssami N. A systematic review of the effectiveness of magnetic
resonance imaging (MRI) as an addition to mammography and ultrasound
in screening young women at high risk of breast cancer. Eur J Cancer. 2007;
43(13):1905–17.
29. Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA,
Eeles RA, Kaas R, Draisma G, Ramsay EA, et al. Differences in natural history
between breast cancers in BRCA1 and BRCA2 mutation carriers and effects
of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer
Epidemiol Biomark Prev. 2012;21(9):1458–68.
30. Narayan AK, Visvanathan K, Harvey SC. Comparative effectiveness of breast
MRI and mammography in screening young women with elevated risk of
developing breast cancer: a retrospective cohort study. Breast Cancer Res
Treat. 2016;158(3):583–9.
31. Vreemann S, Gubern-Merida A, Lardenoije S, Bult P, Karssemeijer N,
Pinker K, Mann RM. The frequency of missed breast cancers in women
participating in a high-risk MRI screening program. Breast Cancer Res
Treat. 2018;169(2):323-31.
32. Gubern-Merida A, Vreemann S, Marti R, Melendez J, Lardenoije S, Mann RM,
Karssemeijer N, Platel B. Automated detection of breast cancer in false-
negative screening MRI studies from women at increased risk. Eur J Radiol.
2016;85(2):472–9.
33. Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl
CC, Trop I, Hooning MJ, Mandel R, et al. Contribution of mammography to
MRI screening in BRCA mutation carriers by BRCA status and age: individual
patient data meta-analysis. Br J Cancer. 2016;114(6):631–7.
34. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Bohm-Velez M,
Mahoney MC, Evans WP 3rd, Larsen LH, et al. Detection of breast cancer
with addition of annual screening ultrasound or a single screening MRI to
mammography in women with elevated breast cancer risk. JAMA. 2012;
307(13):1394–404.
35. Lang K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S.
Performance of one-view breast tomosynthesis as a stand-alone breast
cancer screening modality: results from the Malmo Breast Tomosynthesis
Screening Trial, a population-based study. Eur Radiol. 2016;26(1):184–90.
Vreemann et al. Breast Cancer Research  (2018) 20:84 Page 11 of 12
36. Lang K, Andersson I, Zackrisson S. Breast cancer detection in digital breast
tomosynthesis and digital mammography-a side-by-side review of
discrepant cases. Br J Radiol. 2014;87(1040):20140080.
37. Kuhl CK. Abbreviated breast MRI for screening women with dense breast:
the EA1141 trial. Br J Radiol. 2017:20170441. [Epub ahead of print].
38. Svahn TM, Houssami N, Sechopoulos I, Mattsson S. Review of radiation dose
estimates in digital breast tomosynthesis relative to those in two-view full-
field digital mammography. Breast. 2015;24(2):93–9.
39. Clauser P, Nagl G, Helbich TH, Pinker-Domenig K, Weber M, Kapetas P,
Bernathova M, Baltzer PAT. Diagnostic performance of digital breast
tomosynthesis with a wide scan angle compared to full-field digital
mammography for the detection and characterization of microcalcifications.
Eur J Radiol. 2016;85(12):2161–8.
40. Bleyer A, Welch HG. Effect of three decades of screening mammography on
breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005.
41. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E.
Overdiagnosis in mammographic screening for breast cancer in Europe: a
literature review. J Med Screen. 2012;19(Suppl 1):42–56.
Vreemann et al. Breast Cancer Research  (2018) 20:84 Page 12 of 12
